General Information of Drug Therapeutic Target (DTT) (ID: TTZCG4L)

DTT Name Phosphodiesterase 3 (PDE3)
Synonyms Phosphodiesterase III; PDE3; Cyclic GMP inhibited phosphodiesterase; Cyclic AMP phosphodiesterase III; CGI-PDE; CAMP phosphodiesterase III
Gene Name PDE3
DTT Type
Successful target
[1]
BioChemical Class
Phosphoric diester hydrolase
UniProt ID
NOUNIPROTAC
TTD ID
T33754

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
7 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [2]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [3]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [4]
Inamrinone Lactate DMRMFP4 Cardiac disease BA00-BE2Z Approved [1]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [2]
Olprinone DMWBQKU Heart failure BD10-BD13 Approved [5]
Oxtriphylline DMLHSE3 Cough MD12 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Approved Drug(s)
7 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
K-134 DMD4OK0 Arteriosclerosis BD40 Phase 2 [6]
Org-30029 DMDZ4R2 Heart failure BD10-BD13 Phase 2 [7]
RPL-554 DMLD4VQ Allergic rhinitis CA08.0 Phase 2 [8]
Tipelukast DMS9BDQ Asthma CA23 Phase 2 [9]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [10]
349U85.HCL DMDFA3E Cardiovascular disease BA00-BE2Z Phase 1 [11]
SDZ-MKS-492 DML6QJN Asthma CA23 Phase 1 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
13 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
NSP-805 DMH2QBM Heart failure BD10-BD13 Discontinued in Phase 2 [13]
OPC-8490 DM9ORUL Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [14]
Org-9731 DMZEV63 Heart failure BD10-BD13 Discontinued in Phase 2 [15]
Pumafentrine DMI8T41 Asthma CA23 Discontinued in Phase 2 [16]
Tolafentrine DMEROU4 Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [17]
NIP-520 DMMT7BC Asthma CA23 Discontinued in Phase 1 [18]
R 80122 DMU93JL Cardiovascular disease BA00-BE2Z Discontinued in Phase 1 [19]
Benafentrine dimaleate DMXH3A2 Sepsis 1G40-1G41 Terminated [20]
Org-9935 DMRZCH4 Asthma CA23 Terminated [21]
SDZ-ISQ-844 DMSZJUM Asthma CA23 Terminated [22]
Siguazodan DM98K76 Allergy 4A80-4A85 Terminated [23]
UD-CG-212 DM9FT5E Heart failure BD10-BD13 Terminated [24]
ZARDAVERINE DMC38FO Chronic obstructive pulmonary disease CA22 Terminated [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Discontinued Drug(s)
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostamide DMBVIKY Discovery agent N.A. Investigative [26]
------------------------------------------------------------------------------------

References

1 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
4 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
5 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
6 A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1.
7 Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
8 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
9 Company report (MediciNova)
10 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
11 Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63.
12 Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5.
13 [The effect of phosphodiesterase type 3 inhibitor on chorio-retinal blood flow in rabbits eyes].Nippon Ganka Gakkai Zasshi.2002 Oct;106(10):615-20.
14 Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15;93(4):817-25.
15 Effects of a novel cardiotonic agent, Org 9731, on force and aequorin light transients in intact ventricular myocardium of the dog: involvement of ... J Card Fail. 1995 Mar;1(2):143-53.
16 The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.PLoS One.2013;8(2):e56867.
17 Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
18 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
19 Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14.
20 Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn J Pharmacol. 1995 Feb;67(2):149-56.
21 The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques.Contraception.2008 Apr;77(4):303-7.
22 [Effects of SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isozyme type III/IV inhibitor, on the release of histamine from human peripheral leukocytes].Arerugi.1997 May;46(5):426-32.
23 Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide. Acta Biomed. 2008 Aug;79(2):110-6.
24 Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Br J Pharmacol. 1992 Sep;107(1):127-33.
25 Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl.1991;34:379-402.
26 Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001 Jan;12(1):79-83.